CONSIDERATIONS TO KNOW ABOUT β-AMYLOID (1-42)�?HUMAN TFA

No adverse results on embryo-fetal advancement had been observed in pregnant rabbits treated orally with doses approximately a hundred mg/kg/day elafibranor, which generated systemic exposures (combined AUC for elafibranor and GFT1007) throughout the duration of organogenesis which were lower than the human publicity. Administration of 300 mg/kg/da